|
CA2924393A1
|
|
Markers for amyotrophic lateral sclerosis (als) and presymptomatic alzheimer's desease (psad)
|
|
WO2014210341A2
|
|
Products and methods relating to micro rnas and cancer
|
|
US2014287949A1
|
|
Multiplex assay for members of binding pairs
|
|
WO2014071082A2
|
|
Detection of brain cancer types
|
|
WO2014059370A1
|
|
Improved high throughput system for genetic studies
|
|
WO2014059357A1
|
|
Automated quantification of microorganism growth parameters through temporally resolved microscopic imaging
|
|
US2014073524A1
|
|
Markers and methods for detecting posttraumatic stress disorder (ptsd)
|
|
EP2859119A2
|
|
Complex rna composition of bodily fluids
|
|
WO2013123440A1
|
|
Rnase h-based rna profiling
|
|
US2013193317A1
|
|
Methods of using halogenated peptides as internal standards for liquid chromatography-mass spectrometry
|
|
US2013225428A1
|
|
Liver disease markers
|
|
WO2013006815A1
|
|
Methods and compositions to modulate antiviral and immune activity responses
|
|
WO2012135067A1
|
|
Cellular response assay for biofluid biomarker discovery and detection
|
|
WO2012129126A1
|
|
Diagnosis and treatment of chronic lymphocytic leukemia (cll)
|
|
WO2011133907A2
|
|
Methods to increase and harvest desired metabolite production in algae
|
|
US2011230425A1
|
|
Compositions for protection and cellular delivery of interfering RNA
|
|
EP2531612A1
|
|
Methods and compositions for profiling rna molecules
|
|
WO2011038400A1
|
|
Use of gene expression signatures to determine cancer grade
|
|
CN102803955A
|
|
New biomarkers for liver injury
|
|
CN102510903A
|
|
Improvements in mass spectrum-based identification and quantitation of proteins and peptides
|
